FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBristol-Myers Squibb Company Ce
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CELG-RI
Bristol-Myers Squibb Company Ce Stock AnalysisComprehensive stock analysis for Bristol-Myers Squibb Company Ce (CELG-RI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCELG-RI
CELG-RI
Bristol-Myers Squibb Company Ce
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CELG-RI
  1. Home
  2. Stocks
  3. Bristol-Myers Squibb Company Ce
CE

Bristol-Myers Squibb Company Ce

🇺🇸CELG-RI•NYSE
CE

Bristol-Myers Squibb Company Ce

🇺🇸CELG-RI•NYSE
Market cap
$143.23B
P/E ratio
13.26

Your view on CELG-RI

Mkt Cap
$143.23B
P/E
13.26
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Bristol-Myers Squibb Company Ce

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Christopher S. Boerner
Headquarters
US
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Christopher S. Boerner
Headquarters
US
Description

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

The company was founded in August 1933 and is headquartered in Princeton, NJ.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Bristol-Myers Squibb Company Ce from FRC's valuation model, read against the market price. CELG-RI last traded at $0.16, 13.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Bristol-Myers Squibb Company Ce. Starting points for Bristol-Myers Squibb Company Ce: P/E 13.3, EPS $4.52, beta -0.47 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Bristol-Myers Squibb Company Ce. Trailing twelve-month EPS for Bristol-Myers Squibb Company Ce stands at $4.52. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.59$1.45$6.93$6.55
Low estimate$1.59$1.45$6.93$6.55
High estimate$1.59$1.45$6.93$6.55
No. of analysts1111
Year-ago EPS$1.26$1.58$3.45—
Growth+26.5%−8.2%+100.8%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$12.64B$11.16B$49.55B$48.07B
Low estimate$12.64B$11.16B$49.55B$48.07B
High estimate$12.64B$11.16B$49.55B$48.07B
No. of analysts1111
Year-ago revenue$12.50B$11.49B$48.20B—
Growth+1.1%−2.9%+2.8%—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Bristol-Myers Squibb Company Ce. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CELG-RI20 companies
Compare CELG-RI with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AMGNAmgen Inc.HealthcareDrug Manufacturers - General$240.1B
CVSCVS Health CorporationHealthcareMedical - Healthcare Plans$104.1B
GILDGilead Sciences, Inc.HealthcareDrug Manufacturers - General$209.6B
GSKGSK plcHealthcareDrug Manufacturers - General$97.5B
HCAHCA Healthcare, Inc.HealthcareMedical - Care Facilities$99.5B
MCKMcKesson CorporationHealthcareMedical - Distribution$125.2B
MDTMedtronic plcHealthcareMedical - Devices$128.8B
PFEPfizer Inc.HealthcareDrug Manufacturers - General$159.9B
More Medical - Pharmaceuticals companies
TickerTypeCompanySectorExchangeMkt cap
HTPRFHTC Purenergy Inc.HealthcareOTC$8,153
HTSUYHisamitsu Pharmaceutical Co., Inc.HealthcareOTC$1.9B
HYHYHydrogen Hybrid Technologies, Inc.HealthcareOTC$9,375
INBPIntegrated BioPharma, Inc.HealthcareOTC$8.5M
INNO.CNInnoCan Pharma CorporationHealthcareCNQ$36.1M
IPAHInterpharm Holdings, Inc.HealthcareOTC$270,768
ISHIIslet Holdings, Inc.HealthcareOTC$5
ITNSItonis, Inc.HealthcareOTC$761,705
IYXIInyx, Inc.HealthcareOTC$5,234
JDHIFJD Health International Inc.HealthcareOTC$24.3B
JDHIYJD Health International Inc.HealthcareOTC$29.1B
KNSAKiniksa Pharmaceuticals, Ltd.HealthcareNASDAQ$7.5B
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Bristol-Myers Squibb Company Ce, and how their positions are changing. At a $143.23B market value, institutional positions materially move Bristol-Myers Squibb Company Ce's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Bristol-Myers Squibb Company Ce executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Bristol-Myers Squibb Company Ce. Coverage tracks Bristol-Myers Squibb Company Ce within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Bristol-Myers Squibb Company Ce.

CELG-RI AnalysisGood
Past
5
Growth
2
Health
3
Profit
5
Value
3

News

Latest Market News